TL;DR
Get the latest gadgets delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
FDA vaccine advisory committee unanimously recommended approval for Moderna’s mRNA flu vaccine after a contentious review process. The decision follows a previous agency rejection and now advances the vaccine toward potential market release.
FDA vaccine advisory committee members unanimously voted 9-0 to recommend approval of Moderna’s mRNA seasonal flu vaccine, mRNA-1010, after a period of internal agency controversy and initial rejection. This development marks a significant step toward making the vaccine available later this year, pending final FDA approval and CDC recommendation.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed data from Moderna’s Phase 3 trials involving over 40,000 adults aged 50 and older, which showed the vaccine was approximately 27% more effective than standard flu shots. Additional data from nearly 3,000 adults aged 65 and older indicated that the vaccine produced stronger immune responses than high-dose flu vaccines, which are typically recommended for this age group. The safety profile was generally positive, with no significant safety concerns raised during the review.
Prior to this, the FDA faced internal controversy when a Trump-era official refused to review Moderna’s application in February, claiming the trial data was not adequate because it did not compare efficacy directly against a high-dose vaccine in older adults. This decision was later reversed after widespread criticism, allowing the review to proceed. The advisory committee’s support now positions the vaccine favorably for final approval, which the FDA is expected to decide on by August 5.
Implications of the Committee’s Unanimous Support
The committee’s unanimous vote is a strong indicator that the vaccine meets safety and efficacy standards, which could lead to expedited approval by the FDA. This approval would provide an additional tool for seasonal flu prevention, especially given the potential for mRNA technology to enable rapid updates to match circulating strains. It also signals a shift in regulatory attitudes following recent internal agency disputes, underscoring the importance of scientific consensus in vaccine approvals.
Products Worth Considering
DJI Mic 3 Wireless Microphone Kit (2 Transmitters, 1 Receiver, Charging Case)
Kindle Paperwhite Signature Edition 32GB (2024) – Auto-adjusting front light, wireless charging, weeks of battery life – Metallic Black
Bose QuietComfort Wireless Noise Cancelling Headphones, Black
As an affiliate, we earn on qualifying purchases.
Background of FDA’s Vaccine Review Controversies
In February, a Trump-appointed FDA official rejected Moderna’s vaccine application without review, citing concerns over trial design. This decision was met with criticism from scientific and public health communities, leading to a reversal the following week. The controversy was part of broader internal disagreements within the FDA, which also included rejection of a gene therapy for Huntington’s disease. The agency’s internal conflicts have highlighted the challenges of regulatory decision-making during politically charged periods, although the recent committee vote reflects a return to scientific consensus.
“The studies presented today were very well conducted and demonstrate robust efficacy.”
— an anonymous researcher
Remaining Uncertainties in the Approval Process
It is still unclear whether the FDA will grant final approval by the August 5 deadline, although the committee’s support is a positive sign. Additionally, the upcoming CDC advisory committee’s recommendation is uncertain, especially given the current legal challenges to the CDC’s advisory process. The impact of the ongoing legal injunction against the CDC’s vaccine advisory committee may delay or complicate the final recommendation for widespread use.
Next Steps Toward Vaccine Availability
The FDA is expected to make a final decision on approval by August 5. If approved, Moderna aims to release the vaccine later this year. The vaccine will then require a recommendation from the CDC’s Advisory Committee on Immunization Practices (ACIP). However, the ACIP’s ability to issue recommendations may be delayed due to ongoing legal challenges to its appointment process. Once both approvals are in place, the vaccine could become available for public use, potentially improving flu prevention strategies for the upcoming season.
Key Questions
What does the committee’s vote mean for Moderna’s flu vaccine?
The 9-0 vote indicates strong scientific support for the vaccine’s safety and efficacy, increasing the likelihood of final FDA approval.
When will the vaccine be available to the public?
If approved by the FDA by August 5, Moderna plans to release the vaccine later this year, pending CDC recommendations.
Why was there controversy over the FDA’s review process?
Initially, a Trump-era official refused to review Moderna’s application, citing trial design concerns, which was later reversed after widespread criticism.
What are the advantages of Moderna’s mRNA flu vaccine?
The vaccine has shown improved efficacy over standard flu shots and can be developed rapidly to match circulating strains, offering better preparedness for future flu seasons.
Could legal issues delay the vaccine’s approval?
Yes, ongoing legal challenges to the CDC’s advisory committee might delay final recommendations, affecting the vaccine’s availability.
Source: Hacker News
